Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$168.02
-1.1%
$169.61
$111.09
$183.00
$10.39B0.38506,386 shs333,974 shs
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
$25.59
$25.59
$9.90
$25.61
$2.21B0.191.29 million shs600 shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$71.56
+2.0%
$78.80
$69.12
$118.21
$4.86B0.12983,799 shs1.40 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$11.48
+0.3%
$11.16
$8.73
$13.06
$7.78B1.155.74 million shs5.18 million shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-1.11%-3.92%-5.02%+5.59%+24.27%
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
+1.97%-13.85%-9.64%-28.13%-38.73%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+0.35%-1.29%+0.26%+10.17%+4.36%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.5568 of 5 stars
4.53.00.00.02.71.70.6
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
4.6482 of 5 stars
3.42.00.04.23.92.51.9
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.7991 of 5 stars
3.63.00.00.02.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$223.0732.76% Upside
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
0.00
N/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
2.83
Moderate Buy$131.2083.34% Upside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
3.25
Buy$16.5043.73% Upside

Current Analyst Ratings Breakdown

Latest DCPH, ASND, ROIV, and LNTH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/16/2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
7/11/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$213.00 ➝ $243.00
7/10/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$19.00
7/3/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$250.00
6/23/2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$122.00 ➝ $109.00
6/18/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
6/13/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$215.00 ➝ $224.00
6/9/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$201.00 ➝ $216.00
6/3/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$196.00 ➝ $201.00
5/28/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
5/12/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.00
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$393.54M26.11N/AN/A($1.88) per share-89.37
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
$174.91M12.65N/AN/A$4.38 per share5.84
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.53B3.23$7.24 per share9.89$15.65 per share4.57
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$29.05M268.65N/AN/A$7.45 per share1.54
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$409.12M-$6.28N/A700.08N/A-93.22%N/A-33.29%9/2/2025 (Estimated)
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
-$194.94M-$2.21N/AN/AN/A-108.86%-52.42%-40.05%N/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$312.44M$3.5220.3311.34N/A16.55%36.99%20.55%7/30/2025 (Estimated)
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$171.98M-$0.25N/AN/AN/A-225.71%-14.76%-13.69%8/6/2025 (Estimated)

Latest DCPH, ASND, ROIV, and LNTH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q1 2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.23N/AN/AN/AN/AN/A
7/30/2025Q2 2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.65N/AN/AN/A$389.69 millionN/A
5/29/2025Q4 2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.16-$0.31-$0.15-$0.29$62.17 million$7.57 million
5/7/2025Q1 2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.64$1.53-$0.11$1.02$377.37 million$372.76 million
5/1/2025Q1 2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$1.56-$1.66-$0.10-$1.66$98.56 million$123.97 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
N/AN/AN/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
1.04
0.71
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
N/A
4.19
3.94
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
0.49
5.74
5.46
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
33.47
33.47

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
70.96%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
99.06%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
4.67%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
2.00%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
7.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,01761.15 million36.69 millionOptionable
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
30086.48 million82.44 millionOptionable
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
70069.19 million67.80 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860679.81 million626.10 millionOptionable

Recent News About These Companies

Roivant Sciences Ltd. (ROIV) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$168.02 -1.88 (-1.11%)
Closing price 07/21/2025 04:00 PM Eastern
Extended Trading
$171.50 +3.48 (+2.07%)
As of 07/21/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Deciphera Pharmaceuticals stock logo

Deciphera Pharmaceuticals NASDAQ:DCPH

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Lantheus stock logo

Lantheus NASDAQ:LNTH

$71.56 +1.38 (+1.97%)
Closing price 07/21/2025 04:00 PM Eastern
Extended Trading
$71.86 +0.30 (+0.42%)
As of 07/21/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$11.48 +0.04 (+0.35%)
Closing price 07/21/2025 04:00 PM Eastern
Extended Trading
$11.48 +0.00 (+0.04%)
As of 07/21/2025 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.